Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matija Tomsic

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
The Journal of Rheumatology|January 17, 2017
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA CollaborationKaterina Chatzidionysiou, Elisabeth Lie, Galina Lukina, et al.
Arthritis Research & Therapy|January 10, 2012
International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysisKatja Lakota, Gerhard G Thallinger, Snezna Sodin-Semrl, et al.
Annals of the Rheumatic Diseases|February 25, 2011
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndromeRaphaèle Seror, Philippe Ravaud, Xavier Mariette, et al.
Annals of the Rheumatic Diseases|January 21, 2014
Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)Raphaèle Seror, Elke Theander, Johan G Brun, et al.
Rheumatology (Oxford, England)|March 24, 2022
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritisMichael Nissen, Bénédicte Delcoigne, Daniela Di Giuseppe, et al.
RMD Open|September 20, 2020
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaborationBrigitte Michelsen, Ulf Lindström, Catalin Codreanu, et al.
Annals of the Rheumatic Diseases|August 22, 2019
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaborationLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Johan Askling, et al.
Rheumatology (Oxford, England)|July 5, 2014
Validation of the classification criteria for cryoglobulinaemic vasculitisLuca Quartuccio, Miriam Isola, Laura Corazza, et al.
Arthritis Care & Research|January 18, 2021
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European CountriesBrigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, et al.
The Lancet Regional Health. Europe|August 21, 2023
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
The Journal of Rheumatology|January 17, 2017
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA CollaborationKaterina Chatzidionysiou, Elisabeth Lie, Galina Lukina, et al.
Arthritis Research & Therapy|January 10, 2012
International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysisKatja Lakota, Gerhard G Thallinger, Snezna Sodin-Semrl, et al.
Annals of the Rheumatic Diseases|February 25, 2011
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndromeRaphaèle Seror, Philippe Ravaud, Xavier Mariette, et al.
Annals of the Rheumatic Diseases|January 21, 2014
Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)Raphaèle Seror, Elke Theander, Johan G Brun, et al.
Rheumatology (Oxford, England)|March 24, 2022
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritisMichael Nissen, Bénédicte Delcoigne, Daniela Di Giuseppe, et al.
RMD Open|September 20, 2020
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaborationBrigitte Michelsen, Ulf Lindström, Catalin Codreanu, et al.
Annals of the Rheumatic Diseases|August 22, 2019
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaborationLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Johan Askling, et al.
Rheumatology (Oxford, England)|July 5, 2014
Validation of the classification criteria for cryoglobulinaemic vasculitisLuca Quartuccio, Miriam Isola, Laura Corazza, et al.
Arthritis Care & Research|January 18, 2021
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European CountriesBrigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, et al.
The Lancet Regional Health. Europe|August 21, 2023
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
Pageof 5